Rev. OFIL 2017, 27;1:61-66
Fecha de recepción: 07/01/2016 – Fecha de aceptación: 20/09/2016
Recuero Galve L1, Mulet Alberola AM2, Sánchez Gundín J1, Mejía Recuero M2, Marcos Pérez G2, Barreda Hernández D3
1 Licenciada en Farmacia. Residente de Farmacia Hospitalaria
2 Licenciada en Farmacia. Especialista en Farmacia Hospitalaria
3 Licenciada en Farmacia. Jefe de Servicio
Servicio de Farmacia. Hospital Virgen de la Luz. Gerencia de Atención Integrada de Cuenca (España)
Lidia Recuero Galve
Hermandad Donantes de Sangre, s/n
Correo electrónico: firstname.lastname@example.org
Objetive: To evaluate effectiveness, safety and level of satisfaction of patients with multiple sclerosis (MS) treated with fampridine.
Methods: Observational, descriptive, prospective study (October 2013-April 2014) in a second level hospital. Pharmaco-therapeutical (Farmatools®) and medical record (MambrinoXXI®) of patients treated with fampridine during study period were reviewed. To evaluate: effectiveness with timed 25-foot walk (T25FW) initial and after 14 days; safety: adverse events (AE) presented by patients; level of satisfaction: Treatment Satisfaction Questionnaire for Medication (TSQM) (version 1.4).
Results: 24 patients (18 women) were treated with fampridine. Medium age 48.8±8.3 years. Effectiveness: T25FW initial was 23.55±12.26 seconds and after 14 days was 17.82±8.5 seconds. Two women diagnosed of relapsing-remitting MS and EDSS score of 4 and 6 stopped treatment because of no improvement. Safety: 10 patients no presented AE. The AE more frequent were constipation in 4 patients, sleeplessness and headache in 3 patients, dizziness, nervousness and high levels of transaminases in 2 patients. 5 patients stopped treatment because of AE. 18 patients completed TSQM. Global satisfaction was 11.6±3.3 (maximum score 17).
Conclusions: Fampridine has demonstrated effectiveness due to reduce 6 seconds the T25FW in 81.5% patients and the TSQM valuation was satisfactory. 20.8% of patients stopped the treatment because of AE and 41.6% of patients no presented any AE. Global satisfactory was high (11.6 vs. 17) and this factor indicate the treatment achieved the patients expectations.
Key Words: Fampridine, multiple sclerosis, patient satisfaction.